Integra hopes this deal will grow its revenue to $2 billion sooner than expected.
Celgene's rebound off the January lows could soon develop into a fresh move higher.
Here's why the pharmaceutical company is a solid addition to your portfolio.
Ardelyx, Acorda Therapeutics and Medicines Co. were among the premarket biotech movers on Wednesday.
Target (TGT), Best Buy (BBY), and Gap (GPS) among the retailers whose chief executives will attend a White House meeting.
Cigna's suit seeks declaratory judgment that it lawfully terminated the merger agreement and is entitled to a $1.85 billion reverse termination fee and additional damages exceeding $13 billion.
The largest shareholder of Immunomedics, VenBio, asks for an injunction against its partnership with Seattle Genetics.
Stocks are in flux as Wall Street digests comments from Federal Reserve Chair Yellen Tuesday.
President Donald Trump is facing two pressing policy changes in the early weeks of his new administration: Tax reform and a replacement of the Affordable Care Act.
TheStreet's Adam Feuerstein defends Sarepta Therapeutics
No decision has been made to enter into any transaction at this time, said the senior living communities operator's non-executive chairman on an earnings call Tuesday.
Tuesday's developments would give Cigna leverage if it tries to escape from its $54 billion agreement to merge with Anthem.
Pacific Biosciences of California, AMAG Pharmaceuticals and Global Blood Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
Gilead Sciences' bictegravir suppressed HIV better than rival Glaxo's dolutegravir.
With sales of its hepatitis C drugs falling and an oncology pipeline that has largely disappointed, bictegravir is vitally important for Gilead to defend and grow its dominant HIV franchise.